Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 845
An HIV Vaccine
In this episode of PxPulse, Dr. Nina Russell, Director of TB & HIV Research and Development for the Bill and Melinda Gates foundation, talks about where she sees promise in the science, the goals for an HIV vaccine, and why it has an essential role to play, alongside the scale up of PrEP.
Prevention Option:
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
Diversity, Equity and Access to HIV Research
On May 2, 2024, AVAC staffer Jessica Salzwedel gave a presentation on diversity, equity and access in HIV research at the Ending the HIV Epidemic Conference at Weill Cornell Medicine. Check out the full presentation in PDF format. “When we...
Prevention Option:
Cabotegravir Long-Acting Injectable for Prevention
Afrocab has developed a FAQ (below) that covers the topics of PrEP and explains how CAB-LA works, is taken, and its side effects.
Prevention Option:
Will the Pandemic Accord Fail to Learn the Lessons of the HIV Response?
The Office of the United Nations High Commissioner for Human Rights (OHCHR) highlighted that from the HIV experience we know that if public health measures do not take human rights into account, we will leave marginalised populations behind, fail to address structural barriers to access to quality healthcare, and miss essential interventions altogether.
More and More Evidence that Choice is the Key
AVAC convened three important conversations in the last month on new data that delivered the analysis and evidence that choice and equity in access to PrEP products can make the difference between real-world population-level impact or an epidemic marching on for many years to come.
The Years Ahead in Biomedical HIV Prevention Research
This graphic shows the updated status of large-scale prevention trials through the end of 2024.
Allocation of Non-Commercial CAB for PrEP Supply in Low- and Middle-Income Countries, 2023-2025
Malaysia, Nigeria, Peru, Zambia, and the European Medicines Agency have approved CAB for PrEP; ViiV also made submissions in Canada, Colombia, and the United Kingdom. There are now 13 regulatory approvals and 15 additional submissions that are pending.
Prevention Option:
HIV Vaccine and Antibody Efficacy Trials to Date
This infographic provides a comprehensive overview of HIV vaccine and antibody efficacy trials. Over 20 years and 12 trials, only two positive signals have been observed.
Prevention Option:
Joint Statement on the April 18th Revised Pandemic Accord Draft
The Coalition of Advocates for Global Health and Pandemic Preparedness, a group of organizations advocating for a holistic and equitable approach in pandemic preparedness, offers several revisions to the April 18 revised Pandemic Accord draft.
Prevention Option:
showing 1-10 of 845